IRIS
SCHEINER, BERNHARD
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 824
AS - Asia 762
EU - Europa 549
SA - Sud America 106
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 35
Totale 2.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 775
RU - Federazione Russa 263
SG - Singapore 259
HK - Hong Kong 137
CN - Cina 132
BR - Brasile 82
BD - Bangladesh 64
IT - Italia 62
VN - Vietnam 61
FR - Francia 47
BJ - Benin 42
DE - Germania 41
GB - Regno Unito 35
AT - Austria 27
IN - India 24
KR - Corea 24
CA - Canada 23
JP - Giappone 19
MX - Messico 17
AR - Argentina 13
IQ - Iraq 10
NL - Olanda 10
PL - Polonia 9
SE - Svezia 9
UA - Ucraina 9
FI - Finlandia 8
ZA - Sudafrica 8
ES - Italia 6
IE - Irlanda 6
LT - Lituania 6
EC - Ecuador 5
CH - Svizzera 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
MA - Marocco 3
PH - Filippine 3
TT - Trinidad e Tobago 3
JM - Giamaica 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BS - Bahamas 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
ID - Indonesia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
MY - Malesia 1
PK - Pakistan 1
PS - Palestinian Territory 1
SV - El Salvador 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.299
Salva come PNG Salva come JPEG
Città #
San Jose 139
Hong Kong 133
Singapore 131
Ashburn 88
Council Bluffs 80
Los Angeles 44
Cotonou 42
Santa Clara 36
Beijing 33
Moscow 29
Columbus 28
Lauterbourg 25
Seoul 24
New York 20
Buffalo 19
Ho Chi Minh City 17
Falkenstein 16
Tokyo 16
Vienna 15
São Paulo 14
Orem 13
Hanoi 11
Mexico City 11
Phoenix 11
Brooklyn 10
Chicago 10
Clifton 10
Nuremberg 10
Denver 9
London 9
Stockholm 9
Warsaw 9
Boston 8
Frankfurt am Main 8
Tianjin 8
Chennai 7
Dublin 7
Helsinki 7
Toronto 7
Assago 6
Florence 6
Da Nang 5
Dallas 5
Dhaka 5
Johannesburg 5
Manchester 5
Montreal 5
Poplar 5
Amsterdam 4
Houston 4
Milan 4
Shenzhen 4
Turin 4
Zurich 4
Ankara 3
Atlanta 3
Baie-D'Urfé 3
Boardman 3
Catania 3
Charlotte 3
Elk Grove Village 3
Honolulu 3
Mumbai 3
Roubaix 3
Secaucus 3
Sorocaba 3
Uberlândia 3
Augusta 2
Baghdad 2
Bangkok 2
Basra 2
Bexley 2
Bologna 2
Calgary 2
Cape Town 2
Chengdu 2
Cleveland 2
Deiva Marina 2
Delhi 2
Guangzhou 2
Guayaquil 2
Haiphong 2
Hangzhou 2
Hải Dương 2
Las Vegas 2
Ludhiana 2
Manassas 2
Manila 2
Medellín 2
Montevideo 2
Najaf 2
Naples 2
New Delhi 2
Newark 2
Ninh Bình 2
Paris 2
Providence 2
Querétaro 2
Quito 2
Raleigh 2
Totale 1.299
Salva come PNG Salva come JPEG
Nome #
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 130
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 129
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 113
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 111
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 110
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 98
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 91
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 87
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 87
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 86
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 85
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 84
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 83
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 83
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 82
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 82
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 81
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 73
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 72
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 70
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 69
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 66
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 65
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 63
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 62
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy 51
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 43
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 41
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 36
Totale 2.333
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202459 16 1 6 1 8 0 8 4 0 1 0 14
2024/2025468 8 0 30 2 6 35 57 60 102 58 22 88
2025/20261.645 64 43 79 165 217 129 234 204 125 136 133 116
2026/2027161 73 88 0 0 0 0 0 0 0 0 0 0
Totale 2.333